{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02833792",
      "OrgStudyIdInfo": {
        "OrgStudyId": "STEM105-M-AD"
      },
      "Organization": {
        "OrgFullName": "Stemedica Cell Technologies, Inc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease",
      "OfficialTitle": "A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 20, 2016",
      "StudyFirstSubmitQCDate": "July 13, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 14, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 28, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 29, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Stemedica Cell Technologies, Inc.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Stemedica International SA",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "STUDY OBJECTIVES\n\nPrimary:\n\nTo assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease.\n\nSecondary:\n\nTo assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.",
      "DetailedDescription": "This is a Phase IIa multi-center, randomized, single-blind, placebo-controlled, crossover study in subjects with mild to moderate dementia due to Alzheimer's disease. Only the subject and their caregiver will be blinded to the study treatment. The study will consist of two cohorts of subjects (20 subjects per cohort), randomized in a 1:1 allocation to receive active study drug or placebo. Cohort 1 will receive a single intravenous dose of hMSCs of 1.5 million cells per kilogram body weight on their Study Day 1, and Cohort 2 will receive equal volume of Lactated Ringer's Solution on their Study Day 1. At the six-month time point for each subject after their first infusion, Cohort 1 will receive a single intravenous dose of Lactated Ringer's Solution and Cohort 2 will receive a single intravenous dose of hMSCs at 1.5 million cells per kilogram of the subject's body weight. Approximately 40 subjects will be enrolled in this study. An independent Data and Safety Monitoring Board will conduct periodic safety reviews."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Alzheimer Dementia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Crossover Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "40",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Stem Cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Lactated Ringer's Solution",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Human Mesenchymal Stem Cells and Lactated Riunger's Solution",
            "InterventionDescription": "Intravenous administration",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Stem Cells"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Intravenous administration",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety of aMBMC administration",
            "PrimaryOutcomeDescription": "Number of patients with adverse events will be reported",
            "PrimaryOutcomeTimeFrame": "18 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy of aMBMC administration",
            "SecondaryOutcomeDescription": "Changes is scores relatively to baseline using NIHSS system will be reported for each patient",
            "SecondaryOutcomeTimeFrame": "18 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMales or females between 55-80 years of age.\nDiagnosed with mild to moderate dementia for at least 3 months prior to enrollment, based on the National Institute of Neurological and Communicative\nDisorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) Alzheimer's criteria.\nMMSE between 12-24 (inclusive) at time of enrollment.\nAmyloid-positive florbetapir PET scan.\n\nExclusion Criteria:\n\nPrior treatment with stem cells.\nHistory of intracranial, subdural, or subarachnoid hemorrhage.\nSubjects with baseline brain MRI showing more than four (4) cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as \"possible\" or \"definite\"), and/or one (1) or more areas of superficial siderosis, and/or evidence of a prior macrohemorrhage. MRI must include fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.\nHistory of cancer within the past 5 years, with the exception of localized basal or squamous cell carcinoma.\nHistory of seizure disorder.\nDiagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).\nHistory of cerebral neoplasm.\nMyocardial infarction within six months of enrollment.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "55 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Mini Gill, RN BSN",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "310.582.7437",
            "CentralContactEMail": "Jaya.Gill@providence.org"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Lev Verkh, PhD",
            "OverallOfficialAffiliation": "Stemedica Cell Technologies",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "John Wayne Cancer Institute @ Providence St. John's Health Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Santa Monica",
            "LocationState": "California",
            "LocationZip": "90404",
            "LocationCountry": "United States",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Mini Gill, RN BSN",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "310-582-7437",
                  "LocationContactEMail": "Jaya.Gill@providence.org"
                },
                {
                  "LocationContactName": "Santosh Kesari, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Sponsor information",
            "SeeAlsoLinkURL": "http://stemedica.com"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000544",
            "ConditionMeshTerm": "Alzheimer Disease"
          },
          {
            "ConditionMeshId": "D000003704",
            "ConditionMeshTerm": "Dementia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000024801",
            "ConditionAncestorTerm": "Tauopathies"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000019965",
            "ConditionAncestorTerm": "Neurocognitive Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3037",
            "ConditionBrowseLeafName": "Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6056",
            "ConditionBrowseLeafName": "Dementia",
            "ConditionBrowseLeafAsFound": "Dementia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22155",
            "ConditionBrowseLeafName": "Tauopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20989",
            "ConditionBrowseLeafName": "Neurocognitive Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2192",
            "ConditionBrowseLeafName": "Familial Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Dementia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}